Want to see ES:RJF full AI Analyst Report?
Top Page
LABORATORIO REIG JOFRE
(BME:RJF)
Select Model
Select Model
Rating:46Neutral
Price Target:
€2.50
▼(-6.72% Downside)
Action:Reiterated
Date:03/07/26
The score is weighed down primarily by the 2025 financial setback—sharp revenue decline, heavily compressed margins, and a swing to negative free cash flow—alongside increased leverage. Technicals add further pressure with a clear downtrend and negative momentum. Valuation is also a headwind due to a high P/E, only partly offset by a modest dividend yield.
Positive Factors
Diversified pharma + CDMO business model
A dual revenue model—branded/specialty pharmaceuticals plus CDMO services—provides durable revenue diversification. Long-term, contract manufacturing can smooth utilization and margins, while product sales preserve market exposure, reducing reliance on any single product or client.
Negative Factors
Sharp 2025 revenue decline & margin hit
A sudden, large revenue drop combined with near-break-even margins is structurally damaging: it erodes pricing power, reduces reinvestment capacity for R&D and commercial effort, and can trigger longer-term market-share losses if recovery is slow or competitors capitalize on weakness.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified pharma + CDMO business model
A dual revenue model—branded/specialty pharmaceuticals plus CDMO services—provides durable revenue diversification. Long-term, contract manufacturing can smooth utilization and margins, while product sales preserve market exposure, reducing reliance on any single product or client.
Read all positive factors
LABORATORIO REIG JOFRE (RJF) vs. iShares MSCI Spain ETF (EWP)
Market Cap
€219.70M
Dividend Yield1.91%
Average Volume (3M)44.99K
Price to Earnings (P/E)49.3
Beta (1Y)0.34
Revenue Growth-3.23%
EPS Growth-60.06%
CountryES
Employees1,331
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.11
Shares Outstanding82,219,240
10 Day Avg. Volume48,066
30 Day Avg. Volume44,988
Financial Highlights & Ratios
PEG Ratio-0.79
Price to Book (P/B)0.96
Price to Sales (P/S)0.63
P/FCF Ratio-15.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.15
Revenue Forecast (FY)€358.95M
LABORATORIO REIG JOFRE Business Overview & Revenue Model
Company Description
Laboratorio Reig Jofre, S.A. is a pharmaceutical company dedicated to the research, development, manufacturing, and commercialization of a diverse range of medicines and nutritional supplements. Its extensive portfolio encompasses prescription dru...
How the Company Makes Money
RJF primarily makes money through (1) selling pharmaceutical products and healthcare items and (2) providing contract development and manufacturing services. Product-related revenue is generated from the commercialization of its own portfolio (inc...
LABORATORIO REIG JOFRE Financial Statement Overview
Summary
Income Statement
52
Neutral
Balance Sheet
68
Positive
Cash Flow
38
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 415.66M | 331.10M | 338.89M | 316.09M | 271.15M | 236.23M |
| Gross Profit | 244.01M | 81.71M | 195.68M | 176.89M | 69.58M | 144.98M |
| EBITDA | 38.46M | 30.48M | 36.18M | 33.89M | 30.44M | 24.66M |
| Net Income | 8.86M | 5.02M | 10.38M | 9.41M | 8.11M | 5.09M |
Balance Sheet | ||||||
| Total Assets | 357.56M | 396.56M | 344.85M | 330.55M | 321.19M | 324.98M |
| Cash, Cash Equivalents and Short-Term Investments | 10.84M | 16.84M | 16.08M | 6.36M | 6.88M | 5.16M |
| Total Debt | 67.06M | 98.53M | 58.52M | 53.49M | 61.24M | 67.38M |
| Total Liabilities | 141.17M | 170.24M | 130.90M | 126.29M | 126.64M | 136.46M |
| Stockholders Equity | 216.42M | 218.07M | 213.97M | 204.35M | 194.63M | 188.59M |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -13.78M | 10.56M | 6.34M | 4.75M | -5.26M |
| Operating Cash Flow | 0.00 | 1.51M | 31.34M | 19.11M | 16.15M | 14.50M |
| Investing Cash Flow | 0.00 | -17.82M | -31.96M | -12.88M | -12.72M | -34.70M |
| Financing Cash Flow | 0.00 | 16.31M | 5.59M | -7.16M | -2.04M | 13.67M |
LABORATORIO REIG JOFRE Technical Analysis
Positive
2.68
Price Trends
2.70
Negative
2.61
Positive
2.68
Positive
Market Momentum
>-0.01
Positive
50.47
Neutral
46.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ES:RJF, the sentiment is Positive. The current price of 2.68 is below the 20-day moving average (MA) of 2.69, below the 50-day MA of 2.70, and below the 200-day MA of 2.68, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 50.47 is Neutral, neither overbought nor oversold. The STOCH value of 46.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ES:RJF.
LABORATORIO REIG JOFRE Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | €899.95M | 20.52 | 45.95% | 3.31% | 11.61% | 7.67% | |
60 Neutral | €2.46B | 46.38 | 3.53% | 1.22% | 12.41% | 342.01% | |
60 Neutral | €2.96B | 22.84 | 20.89% | 1.50% | -3.44% | -5.45% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
53 Neutral | €5.54B | 14.75 | 7.88% | 1.37% | 0.89% | 112.68% | |
51 Neutral | €1.44B | 10.83 | 18.13% | 3.51% | 23.66% | -28.51% | |
46 Neutral | €219.70M | 49.26 | 2.03% | 1.91% | -3.23% | -60.06% |
* General Sector Average
ES:RJF
LABORATORIO REIG JOFRE
2.66
-0.31
-10.32%
ES:ALM
Almirall
11.34
0.84
7.99%
ES:CBAV
Clinica Baviera
55.20
14.78
36.56%
ES:FAE
Faes Farma
4.62
0.20
4.55%
ES:GRF
Grifols
9.00
-1.25
-12.21%
ES:ROVI
Laboratorios Farmaceuticos Rovi
58.70
4.70
8.69%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.